The present invention includes a number of structural analogues of UK-1. A comparision of the anticancer activity of the UK-1 analogues with their ability to inhibit the growth of methicillin-sensitive and methicillin-resistant
Staphylococcus aureus
demonstrates that a structurally simplified analogue of UK-1 retains the natural product's selective activity against cancer cells. Structurally conservative changes to UK-1 that diminish Mg
2+
-binding ability may result in a dramatic decrease in cancer cell cytotoxicity. The results may establish a minimum structural pharmacophore as well as a functional role for Mg
2+
-binding in the selective cytotoxicity of UK-1.
本发明包括多个UK-1的结构类似物。将UK-1类似物的抗癌活性与其抑制
甲氧西林敏感和
甲氧西林耐药的
金黄色葡萄球菌生长的能力进行比较,结果表明UK-1的一个结构简化类似物保留了该
天然产物对癌细胞的选择性活性。对UK-1的结构保守性改变可能会降低其与Mg2+结合的能力,从而导致对癌细胞的细胞毒性显著降低。结果可能确定了最小的结构药效团以及Mg2+结合在UK-1的选择性细胞毒性中的功能角色。